Skip to content

Relationship of Noninvasive Assessment of Central BP With 10 Years Atherosclerotic CVD in Subclinical Hypothyroidism

Relationship of Noninvasive Assessment of Central Blood Pressure With 10 Years Atherosclerotic Cardiovascular Disease in Subclinical Hypothyroidism

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06607978
Enrollment
100
Registered
2024-09-23
Start date
2024-10-31
Completion date
2026-12-31
Last updated
2024-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subclinical hypothyroïdism

Brief summary

verify Relationship of noninvasive assessment of central arterial blood pressure with 10 years Atherosclerotic Cardiovascular disease (ASCVD) in Subclinical hypothyroidism

Detailed description

Subclinical hypothyroidism (SCH), characterized by elevated thyrotropin (TSH) levels with normal free thyroxine (T3,T4) concentrations, is a prevalent disorder affecting approximately 10% of the adult population. It has been increasingly recognized for its potential impact on cardiovascular health. A 10-year follow-up study highlighted a significant association between elevated serum TSH levels and increased cardiovascular (CV) risk, independent of conventional risk factors. And it demonstrated its association with hypercholesterolemia and atherosclerosis as the leading risk of CVD. Moreover, in a recent meta-analysis, subclinical hypothyroidism was shown actually be correlated with an increased risk of CVD and mortality. Monitoring thyroid function underscores the potential importance of cardiovascular (CV) risk assessment, for patients with subclinical hypothyroidism (SCH). Incorporating thyroid function tests, such as TSH and free thyroxine (FT4) levels, alongside non-invasive central arterial blood pressure monitoring, provides a comprehensive understanding of a patient's CV risk. This integrated approach enables early identification and targeted interventions, ultimately improving patient outcomes and reducing the incidence of CVD among those with SCH. One of the earliest functional changes underlying ASCVD is Arterial stiffening it reflects a variety of pathologies, including atherosclerosis. As an important determinant of cardiovascular health, arterial stiffness can contribute to increased blood pressure and reduces vessels' capacity to buffer the pulsatile flow when the heart contracts, which are significant risk factors for predicting ASCVD. For continuous non-invasive central arterial blood pressure monitoring, the auscultatory method or The Oscillometric technique can be used. These methods provide valuable insights into the health of the central arteries, which are crucial in understanding the cardiovascular risk profile of patients with SCH.

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18-70 * Both sex

Exclusion criteria

* Patients had thyroidectomy operation * Patients with a history of encompassing acute coronary syndrome (ACS). * Myocardial infarction (MI). * Coronary heart disease (CHD). * Cerebrovascular diseases or other arterial revascularization

Design outcomes

Primary

MeasureTime frameDescription
Assess the extent to which subclinical hypothyroidism is associated with atherosclerotic cardiovascular disease2025the extent to which subclinical hypothyroidism is associated with atherosclerotic cardiovascular disease

Contacts

Primary ContactMona Abdelhameed, Master
Mona.16266057@med.aun.edu.eg+201015832556
Backup ContactSohair Mostafa, Prof
soheir@aun.edu.eg01069347314

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026